LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Design Therapeutics Inc

Design Therapeutics Inc

Gesloten

10.98 -0.27

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.78

Max

11.39

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.6M -18M
EPS	-0.29
Werknemers	54
EBITDA	-1.5M -20M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+78.02% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	98M 898M
Vorige openingsprijs	11.25
Vorige sluitingsprijs	10.98

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

3.26 / 3.63 Steun & Weerstand

Design Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 mei 2026, 16:33 UTC

Winsten

Belangrijke Marktbewegers

Webull Shares Slide on 1Q Loss, Soaring Costs

22 mei 2026, 21:10 UTC

Winsten

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 mei 2026, 19:47 UTC

Winsten

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mei 2026, 19:17 UTC

Marktinformatie

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mei 2026, 19:10 UTC

Marktinformatie

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mei 2026, 18:38 UTC

Marktinformatie

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mei 2026, 18:35 UTC

Acquisities, Fusies, Overnames

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mei 2026, 18:09 UTC

Marktinformatie

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mei 2026, 17:58 UTC

Marktinformatie

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 mei 2026, 17:54 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

22 mei 2026, 17:54 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 mei 2026, 17:54 UTC

Marktinformatie

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 mei 2026, 17:03 UTC

Marktinformatie

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 mei 2026, 16:54 UTC

Marktinformatie

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 mei 2026, 16:16 UTC

Marktinformatie

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

22 mei 2026, 15:55 UTC

Marktinformatie

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 mei 2026, 15:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 mei 2026, 15:42 UTC

Marktinformatie

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 mei 2026, 15:35 UTC

Marktinformatie

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Peer Vergelijking

Prijswijziging

Design Therapeutics Inc Prognose

Koersdoel

By TipRanks

78.02% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 19.6 USD 78.02%

Hoogste 22 USD

Laagste 15 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Design Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Design Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.26 / 3.63Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.